Louise Ekholm1, J Michelle Kahlenberg2, Sevim Barbasso Helmers3, Anna Tjärnlund3, Srilakshmi Yalavarthi2, Wenpu Zhao4, Nickie Seto4, Zoe Betteridge5, Ingrid E Lundberg3, Mariana J Kaplan4. 1. Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Solna, Sweden louise.ekholm@karolinska.se. 2. Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI. 3. Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Solna, Sweden. 4. Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, NIH, Bethesda, MD, USA. 5. Pharmacy and Pharmacology, University of Bath, Bath, UK.
Abstract
OBJECTIVE: Alterations in phenotype and function of endothelial progenitor cells (EPCs) have been associated with poor vascular outcomes and impaired vascular repair in various conditions. Our hypothesis was that patients with PM and DM have dysregulation of EPCs driven by type I IFN and IL-18 similar to other autoimmune diseases. METHODS: Quantification of circulating EPCs was performed by flow cytometry in patients with PM/DM and matched healthy controls. The ability of EPCs to differentiate into mature endothelial cells was investigated by light and fluorescence microscopy quantification in the presence or absence of PM/DM or control serum, neutralizing antibodies to type I IFN receptor or IL-18. Serum type I IFN activity was quantified by induction of type I IFN-inducible genes in HeLa cells. Circulating IL-18 concentrations were assessed by ELISA. RESULTS: Circulating EPCs were significantly lower in PM/DM patients compared with controls. PM/DM EPCs displayed a decreased capacity to differentiate into mature endothelial cells and PM/DM serum significantly inhibited differentiation of control EPCs. This effect was reversed in the majority of samples with neutralizing antibodies to IL-18 or to type I IFN receptor or by a combination of these antibodies. Patients with associated impairments in EPC function had higher type I IFN serum activity. CONCLUSION: PM/DM is associated with dysregulation of EPC phenotype and function that may be attributed, at least in part, to aberrant IL-18 and type I IFN pathways. The implication of these vasculopathic findings for disease prognosis and complications remains to be determined.
OBJECTIVE: Alterations in phenotype and function of endothelial progenitor cells (EPCs) have been associated with poor vascular outcomes and impaired vascular repair in various conditions. Our hypothesis was that patients with PM and DM have dysregulation of EPCs driven by type I IFN and IL-18 similar to other autoimmune diseases. METHODS: Quantification of circulating EPCs was performed by flow cytometry in patients with PM/DM and matched healthy controls. The ability of EPCs to differentiate into mature endothelial cells was investigated by light and fluorescence microscopy quantification in the presence or absence of PM/DM or control serum, neutralizing antibodies to type I IFN receptor or IL-18. Serum type I IFN activity was quantified by induction of type I IFN-inducible genes in HeLa cells. Circulating IL-18 concentrations were assessed by ELISA. RESULTS: Circulating EPCs were significantly lower in PM/DMpatients compared with controls. PM/DM EPCs displayed a decreased capacity to differentiate into mature endothelial cells and PM/DM serum significantly inhibited differentiation of control EPCs. This effect was reversed in the majority of samples with neutralizing antibodies to IL-18 or to type I IFN receptor or by a combination of these antibodies. Patients with associated impairments in EPC function had higher type I IFN serum activity. CONCLUSION: PM/DM is associated with dysregulation of EPC phenotype and function that may be attributed, at least in part, to aberrant IL-18 and type I IFN pathways. The implication of these vasculopathic findings for disease prognosis and complications remains to be determined.
Authors: Anne P Liao; Mohammad Salajegheh; Remedios Nazareno; Jonathan C Kagan; Ronald G Jubin; Steven A Greenberg Journal: Ann Rheum Dis Date: 2010-12-21 Impact factor: 19.103
Authors: Danieli Andrade; Mimi Kim; Luz P Blanco; S Ananth Karumanchi; Gloria C Koo; Patricia Redecha; Kyriakos Kirou; Angela M Alvarez; Melissa J Mulla; Mary K Crow; Vikki M Abrahams; Mariana J Kaplan; Jane E Salmon Journal: Arthritis Rheumatol Date: 2015-04 Impact factor: 10.995
Authors: D A Isenberg; E Allen; V Farewell; M R Ehrenstein; M G Hanna; I E Lundberg; C Oddis; C Pilkington; P Plotz; D Scott; J Vencovsky; R Cooper; L Rider; F Miller Journal: Rheumatology (Oxford) Date: 2003-07-16 Impact factor: 7.580
Authors: Emily C Somers; Wenpu Zhao; Emily E Lewis; Lu Wang; Jeffrey J Wing; Baskaran Sundaram; Ella A Kazerooni; W Joseph McCune; Mariana J Kaplan Journal: PLoS One Date: 2012-05-14 Impact factor: 3.240
Authors: Takayuki Kishi; Jonathan Chipman; Melvina Evereklian; Khanh Nghiem; Maryalice Stetler-Stevenson; Margaret E Rick; Michael Centola; Frederick W Miller; Lisa G Rider Journal: J Rheumatol Date: 2019-08-01 Impact factor: 4.666